scholarly journals Lobular Breast Cancer in a Male Patient with a Previous History of Irradiation Due to Hodgkin’s Disease

Breast Care ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. 315-318 ◽  
Author(s):  
Srdjan Ninkovic ◽  
Goran Azanjac ◽  
Milan Knezevic ◽  
Dragce Radovanovic ◽  
Dragan Canovic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Patient ◽  
Previous History ◽  
Lobular Breast Cancer ◽  
History Of

scholarly journals Pseudofungi in an Immunocompromised Patient with Breast Cancer and COVID-19

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Nadeem Bilani ◽  
Leah Elson ◽  
Diane Carlson ◽  
Elizabeth Blessing Elimimian ◽  
Zeina Nahleh
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Male Patient ◽  
Immunocompromised Patient ◽  
Recent History ◽  
Pathological Examination ◽  
History Of

Herein, we present a case of a male patient with breast cancer and a recent history of COVID-19 pneumonia, diagnosed with pseudofungi on pathological examination of lymph nodes after mastectomy. Pseudofungi are septate hyphae-like structures that morphologically mimic fungal elements despite the absence of true mycosis and thus predispose to overtreatment if not properly identified. We report a review of similar cases involving this diagnostic mimicker in the literature.

Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect

2018 ◽  
Vol 55 (7) ◽  
pp. 431-441 ◽  
Author(s):  
Giovanni Corso ◽  
Joana Figueiredo ◽  
Carlo La Vecchia ◽  
Paolo Veronesi ◽  
Gabriella Pravettoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Age At Onset ◽  
Genetic Defect ◽  
Prophylactic Surgery ◽  
Current Evidence ◽  
Diffuse Gastric Cancer ◽  
Lobular Breast Cancer ◽  
Clinicopathological Findings ◽  
History Of

Recent studies have reported germline CDH1 mutations in cases of lobular breast cancer (LBC) not associated with the classical hereditary diffuse gastric cancer syndrome. A multidisciplinary workgroup discussed genetic susceptibility, pathophysiology and clinical management of hereditary LBC (HLBC). The team has established the clinical criteria for CDH1 screening and results’ interpretation, and created consensus guidelines regarding genetic counselling, breast surveillance and imaging techniques, clinicopathological findings, psychological and decisional support, as well as prophylactic surgery and plastic reconstruction. Based on a review of current evidence for the identification of HLBC cases/families, CDH1 genetic testing is recommended in patients fulfilling the following criteria: (A) bilateral LBC with or without family history of LBC, with age at onset <50 years, and (B) unilateral LBC with family history of LBC, with age at onset <45 years. In CDH1 asymptomatic mutant carriers, breast surveillance with clinical examination, yearly mammography, contrast-enhanced breast MRI and breast ultrasonography (US) with 6-month interval between the US and the MRI should be implemented as a first approach. In selected cases with personal history, family history of LBC and CDH1 mutations, prophylactic mastectomy could be discussed with an integrative group of clinical experts. Psychodecisional support also plays a pivotal role in the management of individuals with or without CDH1 germline alterations. Ultimately, the definition of a specific protocol for CDH1 genetic screening and ongoing coordinated management of patients with HLBC is crucial for the effective surveillance and early detection of LBC.

scholarly journals Excision of metastatic breast cancer from sternum and reconstruction in two patients with solitary metastatic spread

2020 ◽  
Vol 2020 (8) ◽  
Author(s):  
Saifullah Mohamed ◽  
Khurum Mazhar ◽  
Ahmed Osman ◽  
Akshay Patel ◽  
Lakshmi Srinivasan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Previous History ◽  
Metastatic Breast ◽  
Extent Of Resection ◽  
Left Breast ◽  
Term Survival ◽  
Metastatic Breast Carcinoma ◽  
History Of ◽  
Treated Breast

Abstract Metastatic breast carcinoma is a relatively common clinical entity. However, the prognosis of oligometastatic and polygometastatic disease differs considerably pertaining to five-year survival. Metastatic breast carcinoma to the sternum has been described as early as 1988. We describe two cases in our institution who presented with solitary sternal metastases with a previous history of treated breast cancer. In both cases, there had been a history of previous left breast cancer treated aggressively with surgical resection and adjuvant oncological therapy and maintenance hormonal therapy. Partial sternectomy or total sternectomy for solitary metastatic sternal deposits is well established with relatively low morbidity and mortality and improvement in quality of life and possible improvement in long-term survival. Furthermore, reconstructive options are inherently dependent on extent of resection performed. These techniques can incorporate the use of sternal plates in order to approximate defects and reinforce the sternum in the setting of partial sternectomy.

Case control study of hormone replacement therapy (HRT) and breast cancer in Japanese women

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10012-10012
Author(s):  
M. Takeuchi ◽  
T. Saeki ◽  
M. Sano ◽  
H. Sonoo ◽  
H. Honjo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Menopausal Status ◽  
Previous History ◽  
Case Control ◽  
Japanese Women ◽  
Sensitivity Analyses ◽  
Control Group ◽  
History Of ◽  
Control Study

10012 Background: Some prospective studies in US and UK (represented by Women’s Health Initiative and Million Women Study) show that HRT use may increase the risk of breast cancer. However, it is unclear whether or not this perspective is applicable to Japanese women, due to several factors such as the difference in incidence of breast cancer, difference in HRT prevalence, which are to be concerned in this study. To investigate the relationship between HRT use and breast cancer, a case-control study was conducted in Japan. Methods: We sent self-administered questionnaire to 4,500 cases who have a previous history of confirmed histological breast cancer and 4,500 controls who were selected according to the inclusion criteria. All the subjects were between age 45 and 69 at the time of enrollment. Among these subjects, 3,434 in case group and 2,427 in control group sent back their questionnaire (total 5,861). The datacenter was run in Kitasato Univ. and the statistical analysis was performed using SAS (version 9.1). Control was selected by considering the screening record for GI disease and respiratory disorders, with no previous history of breast cancer, gynecological and hormonal disease at the time of screening. We asked about past history of exposure to the factors supposed to be breast cancer-causing; previous or current use of HRT, age at diagnosis, academic background, BMI, lifestyle habits, age of menarche, birth history, history of breast feeding, family history, use of contraceptive agents and menopausal status. Results: As the main analysis result, 164 (5.0%) out of 3,316 cases and 253 (7.4%) out of 2355 controls had used HRT (Odds ratio 0.432 [95% CI 0.352–0.530]. Conclusions: The result of this study shows that HRT users were less likely to develop breast cancer than never users. However, in this study, there was a difference in the observation period for the past use of HRT between cases and controls. Considering the transition of HRT prevalence in Japan, there may be a possibility that this difference can be a cause of a serious bias for the main analysis result. Further sensitivity analyses are needed to evaluate the robustness of the findings and this point is under consideration. No significant financial relationships to disclose.

Pleomorphic lobular carcinoma in situ: A distinct entity of controversial significance.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 177-177
Author(s):  
Marina De Brot ◽  
Shirin Muhsen ◽  
Victor P. Andrade ◽  
Starr Koslow Mautner ◽  
Melissa Murray ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Previous History ◽  
Prior History ◽  
Lobular Carcinoma In Situ ◽  
Pleomorphic Lobular Carcinoma ◽  
History Of

177 Background: Pleomorphic lobular carcinoma in situ (PLCIS) is an increasingly diagnosed variant of lobular carcinoma in situ. Histologically, it resembles ductal carcinoma in situ (DCIS), leading to controversy over proper management. Yet, the natural history of PLCIS is unknown. Here we describe our experience with PLCIS. Methods: Review of pathology reports (1995–2012) identified 233 cases of LCIS variants. Patients with synchronous ipsilateral DCIS or invasive cancer (IC) were excluded leaving 25 cases for review. Consensus review by 3 pathologists further excluded 7; leaving 18 cases, 12 of which were classified as PLCIS and 6 as LCIS with pleomorphic features (LCIS-PF). (Table) PLCIS was defined by cellular dyshesion, nuclear pleomorphism with a 2-3 fold size variation, conspicuous nucleoli, mitoses and abundant cytoplasm; lesions not meeting all parameters were classified as LCIS-PF. Loss of e-cadherin was confirmed; clinical data were obtained from medical records. Results: Mean patient age at diagnosis of PLCIS/LCIS-PF was 57 yrs (42-67 yrs). All cases presented with imaging abnormalities. A previous history of breast cancer was present in 7/18 (39%) pts (3/7, ipsilateral; 4/7, contralateral). Following PLCIS/LCIS-PF diagnosis, 6/18 (33%) pts underwent mastectomy and 12/18 had excision alone, with (n=3) or without chemoprevention (n=9). Margin status was negative in 4/12 pts; close in 3/12 pts and positive in 5/12 pts undergoing excision. At a median follow-up of 27 mos (2-148 mos), 2/12 pts treated with excision developed ipsilateral breast cancer (1 DCIS; 1 IC). Both had close margins at initial excision; median time to cancer, 54 mos. Conclusions: Pure PLCIS is an uncommon lesion. Synchronous malignancy or prior history of breast cancer are often present in patients with PLCIS, contributing to the difficulty in determining the actual risk conferred by this lesion and appropriate management. Efforts to systematically characterize LCIS variants and prospective documentation of outcomes are needed to clarify the significance of these lesions. [Table: see text]

scholarly journals Diabetic Ketoacidosis With Alpelisib

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A376-A377
Author(s):  
Rebecca Jeun ◽  
Victor Ralph Lavis ◽  
Sonali Thosani
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Metastatic Breast Cancer ◽  
Diabetic Ketoacidosis ◽  
Hormone Receptor ◽  
Previous History ◽  
Metastatic Breast ◽  
Laboratory Evaluation ◽  
Hormone Receptor Positive ◽  
History Of

Abstract Background: Hyperglycemia is a frequently reported adverse effect of alpelisib, an isoform specific phosphoinositide 3 kinase inhibitor, which is recently approved for use in hormone receptor positive advanced or metastatic breast cancer. Though two patients in clinical trials with alpelisib developed diabetic ketoacidosis (DKA), there have been no case reports to date characterizing this complication after drug approval. We present the first case of DKA in patients on alpelisib therapy. Clinical Case: A 55-year-old woman with a history of hormone-receptor positive metastatic breast cancer was started on treatment with fulvestrant and alpelisib. The patient did not have any previous history of diabetes nor gestational diabetes, though she had evidence of prediabetes prior to starting treatment. Patient was non-obese and had a family history of type 2 diabetes. Baseline hemoglobin A1c was 5.6% (n &lt;5.7%) with impaired fasting glucose of 108 mg/dl (n&lt;105 mg/dL) immediately prior to starting therapy. One week after starting alpelisib, she presented to the emergency center in diabetic ketoacidosis. Initial laboratory evaluation showed serum glucose 690 mg/dl, anion gap metabolic acidosis, with undetectable serum bicarbonate and ketonuria. C-peptide on hospital day 1 was found to be 2.8 ng/ml (n 0.5 - 3.4 ng/ml) with a concurrent glucose of 479 mg/dl. GAD65 and Islet Antigen 2 antibodies were negative. Diabetic ketoacidosis quickly resolved with continuous insulin infusion and stopping alpelisib. The patient was able to come off all insulin therapy prior to discharge and was discharged on metformin with adequate glycemic control. Conclusions: Current manufacturer guidelines for alpelisib recommend screening for diabetes mellitus at baseline and monitoring blood glucose and/or fasting plasma glucose weekly for the first two weeks of treatment and monthly thereafter. However, patients with no pre-existing history of diabetes mellitus may be at risk for life-threatening hyperglycemic crises which may develop within a week of initiation of alpelisib and more frequent monitoring may be indicated. The hyperglycemic effect of alpelisib appears to be reversible upon stopping the drug.

Palliation of ulcerative breast lesions with radiation.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 199-199
Author(s):  
Prashant Vempati ◽  
Miriam Knoll ◽  
Kavita Vyas Dharmarajan ◽  
Sheryl Green ◽  
Amy Tiersten ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Lesion ◽  
Radiation Treatment ◽  
Academic Medical Center ◽  
Previous History ◽  
Chemotherapeutic Agents ◽  
Breast Lesions ◽  
Median Dose ◽  
History Of ◽  
The Mean

199 Background: Patients with advanced breast cancer may experience ulcerative breast lesions. Breast cancer with ulcerative lesions has been shown to severely affect a patient’s quality of life (QoL). The role of palliative radiation therapy (RT) in the management of ulcerative breast lesions needs to be further explored. Methods: IRB-approval was obtained to retrospectively review the radiation treatment records for all patients who underwent palliative RT for breast cancer at our urban academic medical center. A total of 13 patients were identified, and we herein report their demographics, treatment characteristics, and clinical outcomes. Results: The mean age of the patients receiving palliative RT for ulcerative breast cancer was 64 years. All patients had stage IV disease when they were evaluated for RT. All patients received prior systemic chemotherapy with a mean of four chemotherapeutic agents, the most common of which was Capecitabine. The mean radiation dose received for palliative RT was 27.54 Gy in 11 fractions with a median dose of 30 Gy in 15 fractions. Six (46%) of the patients received prior RT to the same breast, with a median dose of 59.5 Gy in 31 fractions. Among these six patients, the average interval between initial RT and ulcerative breast lesion was 69.5 months. The median overall survival in all patients since ulcerative breast lesion was 5 months and the mean survival did not differ between patients with previous history of RT and RT-naïve patients (4.50 vs. 4.57; p = 0.95). Six out of the 9 (69%) patients who received ≥ 30 Gy reported clinical improvement, whereas none of the 4 patients who received < 30 Gy reported any benefit. There were no radiation-associated toxicities reported by patients. Conclusions: These data suggest that palliative RT ( ≥ 30 Gy) is an efficacious treatment for ulcerative breast cancer with minimal toxicity. Prior RT should not be a contraindication as patients with previous history of RT have similar outcomes compared to RT-naïve patients.

Moderating Effect of Physical Activity in Prevention of Colorectal and Breast Cancer by Mediterranean Diet in Females of Pakistan

2021 ◽  
Vol 15 (6) ◽  
pp. 1614-1616
Author(s):  
Ubaidullah . ◽  
Huma Tahir ◽  
Liaqat Ali ◽  
Muhammad Tahir ◽  
Zarak Khan
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Colorectal Cancer ◽  
Cancer Prevention ◽  
Mediterranean Diet ◽  
Previous History ◽  
Physical Activities ◽  
Daily Routine ◽  
History Of ◽  
Dietary Plan

Objective: The aim and purpose of the study are to determine how cancer can be prevented by maintaining a good dietary plan and physical activity. To discuss the relationship between diet and cancer prevention, guidelines, and evidence-based strategies to reduce the cancer risk (Jennifer, Karen and Wendy 2016). Cancer prevention food plan should consist of all the right amounts of macronutrients and micronutrients. Dietary guidelines can be adapted to promote health and preventing diet-related chronic diseases—a population that hasa good dietary plan, less prone to the risk of cancer. Study Design:. A cross-sectional study Place and Duration:This study was conducted at Holy Family Hospital and Wapda Hospital of Rawalpindi for duration of six months i.e from June 2020 to December 2020. Methods: Research was conducted on a sample of 58 females. Patients were aged between 18-75 years. Patients’ detailed demographics age,residency and body mass index were recorded after taking informed written consent. Previous history of breast and colorectal cancer were recorded among patients. Consumption and awareness of mediterranean diet among females were assessed. Effectiveness and recommendation of this diet were also observed. Complete data was analyzed by SPSS 24.0 version. Results:Most of the patients 35 (60.34%) were aged between 18-24 years, 12 (20.7%) were between 25-34 years of age and the rest were 11 (18.97%) >35 years of age. Mean age of the patients were 28.74±10.54 years with mean BMI 24.08±9.45 kg/m2. 41(70.7%) was not aware from mediterranean diet and regular take of this diet was found in 15 (25.9%) cases. Physical activities were found among 47 (63.%) cases. Previous history of colorectal cancer was found in 4 (6.9%) cases and breast cancer was found in 26 (44.8%) cases. 42 (72.41%) patients were agree to recommend this diet after read this useful benefits. Conclusion:We concludedin this study that the use of mediterranean diet in daily routine was useful and effective in prevention of breast and colorectal cancer. It can also be prevented by physical activities in daily work. Keywords: Colorectal cancer, breast cancer, physical activity, Mediterranean diet

Sign in / Sign up

Export Citation Format

Share Document